AVI Biopharma Inc.'s (Nasdaq: AVII) muscular dystrophy treatment eteplirsen increased levels of the protein dystrophin but failed to improve walking ability in a midstage clinical trial sending the stock price tumbling 45 cents to $1.09.
Disappointing Results For AVI's Eteplirsen
April 02, 2012 at 13:05 PM EDT